What's happening now

We started a program to identify novel hits that inhibit the interaction between the viral spike protein subunit S1 and human angiotensin-converting enzyme 2 (hACE2).

Malaria is a deadly disease, that affected over 240 million people in 2020, an increase over progress in previous years. Despite advances in malariology, the challenge of finding the right drugs to treat the illness is complex. Find out more about malaria drug discovery in this webinar.

In this webinar we provide an overwiew of application demands for a reliable sample preparation automation and highlight the challenges that need to be overcome to improve lab processes

In this webinar we will present the implementation and capabilities of MS-uHTS as a fully automated screening platform and future applications of MS-uHTS.

In this webinar we will guide you through the process of building your own high-quality library and demonstrate how to analyze content of diverse compound libraries for HTS.

In this webinar we will focus on label-free mass spectromety technology. Pivot Park Screening Centre (PPSC) will present the integration and the first successful campaign of over 0.5 million compounds using label-free mass spectrometry technology.

How to optimise your assay for High Throughput Screening (HTS) at the European Lead Factory (ELF). This was the topic of the latest ELF webinar, which took place on Thursday 28 January.

Watch this webinar to learn about trained immunity, the role of epigenetic targets in trained immunity, hit discovery through ultra-High throughput screening of large libraries & industry standard H2L biological profiling frameworks.

Watch this webinar to learn about Pivot Park Screening Centre (PPSC) contributions to the European Lead Factory (ELF), hit finding efforts for > 70 crowd-sourced drug targets & lessons learnt from assay development and uHTS output within ELF.